In VivoStrong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ah
ScripMerck & Co. presented full data from a Phase III trial testing Keytruda (pembrolizumab) as perioperative treatment in stage III or IVA resected, locally advanced head and neck squamous cell carcin
ScripBristol Myers Squibb is three years away from facing generic and biosimilar competitors for its two top-selling products – Eliquis (apixaban) and Opdivo (nivolumab), which delivered 52% of the company
ScripBristol Myers Squibb raised its full-year 2025 guidance after first quarter sales beat expectations, anticipating greater revenue despite the impact of tariffs imposed on US products shipped into Chin